FindTrial
Sign In

Impact of HBV reactivation on tumor development in hepatocellular carcinoma patients during antitumor therapy

Impact of HBV reactivation on tumor development in hepatocellular carcinoma patients during antitumor therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110767
Enrollment
Unknown
Registered
2025-10-20
Start date
2025-10-22
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Observation group:None

Sponsors

The Fifth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient is aged 18 years or older; 2. Pathologically diagnosed with hepatocellular carcinoma (HCC) via liver biopsy, and developed HBV reactivation during anti-tumor treatment; 3. Child-Pugh classification of Grade A or Grade B (7 points); 4. ECOG Performance Status (PS) score of 0-1; 5. Presence of at least one measurable target lesion according to the mRECIST criteria.

Exclusion criteria

Exclusion criteria: 1. Having any severe comorbidities involving other major organs; 2. Having a history of or current comorbidity with other malignant tumors;3. Having incomplete medical record data.

Design outcomes

Primary

MeasureTime frame
Objective response rate;—

Secondary

MeasureTime frame
Overall survival rate;HBV reactivation rate;Progression-Free Survival;—

Countries

China

Contacts

Public ContactFuchuan Wang

The Fifth Medical Center of Chinese PLA General Hospital

wfc_20002000@163.com+86 199 3775 1775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026